Moderna vs Pfizer (MRNA vs PFE)
Side by side from their SEC filings: revenue, margins, growth, returns and valuation, plus short interest, insider activity and institutional ownership.
Pfizer is the larger company by revenue ($62.6B vs $1.9B) and market value ($156.7B vs $74.8B). Pfizer has grown revenue faster over the last 4 fiscal years (-23.0% cumulative vs -89.5%).
About Moderna
Moderna, Inc. develops medicines based on messenger RNA (mRNA) technology to treat and prevent diseases. Its main products include COVID-19 vaccines Spikevax and mNEXSPIKE, and the respiratory syncytial virus vaccine mRESVIA. The company serves patients globally and is advancing a pipeline of vaccines and therapies for infectious diseases, oncology, and rare diseases.
About Pfizer
Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, markets, sells, and distributes medicines and vaccines worldwide. Its main products include treatments in oncology, internal medicine, vaccines, inflammation, and immunology, serving healthcare providers and patients across developed and emerging markets. Pfizer operates through its Biopharma segment, which manages commercial operations and product portfolios such as primary care, specialty care, oncology, and hospital and biosimilars.
Head to head (MRNA FY2025 vs PFE FY2025)
| Metric | MRNAFY2025 | PFEFY2025 |
|---|---|---|
| Revenue | $1.94B | $62.58B |
| Revenue growth (YoY) | -39.9% | -1.6% |
| Gross margin | — | 74.3% |
| Operating margin | — | — |
| Net margin | — | 12.4% |
| Net income | $-2.82B | $7.77B |
| Diluted EPS | $-7.26 | $1.36 |
| FCF margin | — | 14.5% |
| ROE | -32.6% | 9.0% |
| Long-term debt / equity | 0.07× | 0.71× |
| Market cap | $74.84B | $156.74B |
| P/E | — | 36.2× |
Fundamentals are from each company’s SEC filings (MRNA FY2025, PFE FY2025). ROE is net income over fiscal-year-end equity; long-term debt / equity counts non-current term debt only. P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.
Five-year trend (as reported)
| Revenue | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| MRNA | $18.47B | $19.26B | $6.85B | $3.24B | $1.94B |
| PFE | $81.29B | $91.79B | $59.55B | $63.63B | $62.58B |
Peer standing
These companies are ranked against different peer groups (Moderna vs 71 biotech companies; Pfizer vs 198 pharmaceutical companies), so each is shown against its own peers rather than on one scale.
Moderna
Moderna’s revenue growth of -39.9% ranks in the 14th percentile of the 64 biotech companies reporting it.
Pfizer
No standout rankings: Pfizer sits mid-distribution on most reported metrics.
Short interest
| FINRA settlement data | MRNA | PFE |
|---|---|---|
| Shares sold short | 32.9M | 155.2M |
| Change vs prior settlement | -16.0% | +2.4% |
| Days to cover | 2.53 | 4.90 |
| As of settlement | 2026-09-15 | 2026-09-15 |
Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data; republishing or redistributing it is not permitted. Not presented as a percentage of float. No FINRA endorsement of this product is implied.
Insider activity (last 90 days)
| Form 4 activity (codes P/S) | MRNA | PFE |
|---|---|---|
| Buys | 0 | 3 ($3.0M) |
| Sells | 10 ($49.2M) | 1 ($83,261) |
Non-derivative purchases (code P) and sales (code S) reported on SEC Form 4, which may be open-market or private (grants, exercises and tax withholding excluded). For context, about 15% of covered companies saw any reported insider purchase (code P) in a 90-day window.
Held by the same investors
6 tracked 13F managers hold both Moderna and Pfizer as of their latest quarterly filings: AQR Capital Management, Bridgewater Associates, Citadel Advisors, D. E. Shaw, Millennium Management, Two Sigma Investments. See which superinvestors hold your own portfolio with the smart money checker.
Go deeper
AMGN vs MRNABIIB vs MRNAEXEL vs MRNAGILD vs MRNAMRNA vs NBIXMRNA vs RVMDAll comparisons →
Track MRNA and PFE
Get an alert when either company files something material, see which superinvestors own them, and ask their filings a question with cited answers.
Start monitoring freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filings before relying on them. Comparisons are descriptive (higher or lower on a reported figure), not a rating or a recommendation. Informational only. Not investment advice.